Tad is a member of Reed Smith's Business & Finance - Corporate & Securities Group, including the Life Sciences Transaction team. Tad represents clients involved in sophisticated securities and corporate transactional matters. He is experienced in assisting clients in all stages of the corporate growth cycle.

Tad regularly advises on U.S. public offerings and private placements of debt and equity securities (IPOs, secondary offerings, shelf registration statements, PIPEs and Rule 144A and/or Regulation S private placements), as well as with respect to compliance with ongoing reporting obligations (Proxy Statements and Forms 10-K, 10-Q and 8-K), NYSE and NASDAQ listing requirements (director independence and corporate governance requirements), Sarbanes-Oxley Act of 2002, and annual and special shareholder meeting-related matters (proxy statements, including compensation disclosure, bylaw provisions and review of board committee charters).

Tad also represents issuers, venture groups and investors in various forms of private financings, including private placements, debt and equity bridge financings, and venture capital financings. He also has substantial experience in structuring, negotiating and documenting various complex business transactions, including mergers and acquisitions, recapitalizations and reorganizations, exchange offers, licensing and technology transfer arrangements, and joint venture formations.

In addition to representing clients in capital raising activities, SEC matters and complex transactional matters, Tad has over 20 years of experience representing clients in the negotiation and preparation of a broad range of operational agreements, commercial arrangements and governance matters, such as consulting, licensing, shareholder, operating, partnership, confidentiality and employment agreements and Board of Director, Audit Committees and Compensation Committee representation.